Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Is it time to modify the reverse cholesterol transport model?
Alan R. Tall, … , Nan Wang, Phillip Mucksavage
Alan R. Tall, … , Nan Wang, Phillip Mucksavage
Published November 1, 2001
Citation Information: J Clin Invest. 2001;108(9):1273-1275. https://doi.org/10.1172/JCI14342.
View: Text | PDF
Commentary

Is it time to modify the reverse cholesterol transport model?

  • Text
  • PDF
Abstract

Authors

Alan R. Tall, Nan Wang, Phillip Mucksavage

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Contribution of ABCA1 to macrophage cholesterol efflux, HDL levels, and ...
Contribution of ABCA1 to macrophage cholesterol efflux, HDL levels, and centripetal cholesterol flux. ABCA1 probably has a major role in the efflux of phospholipids and cholesterol from different cells (macrophages, hepatocytes) to apoA-I. This is followed by further growth of the HDL particle, involving the addition of lipids and apoproteins, cholesterol esterification by lecithin-cholesterol acyltransfer (LCAT), and influx of phospholipids under the control of phospholipid transfer protein (PLTP), and eventuates in the formation of mature HDL. Macrophage ABCA1 makes only a minor contribution to the maintenance of circulating HDL, while hepatic expression of ABCA1 probably has a major role in this regard (thick arrow). Studies in ABCA1 KO mice indicate that although ABCA1 has a key role in maintaining HDL levels, overall centripetal flow of cholesterol from periphery to liver appears not to be affected by the absence of ABCA1. Nonetheless, the phenotype of Tangier disease indicates that ABCA1 has an essential role in removing cholesterol deposited in macrophages, but probably not other cells. The amount of cholesterol lost from macrophages is too small to be measured in the overall centripetal flow of cholesterol. Moreover, macrophage-derived cholesterol could be redistributed to VLDL/LDL and taken up in other peripheral tissues, without substantially changing VLDL/LDL cholesterol levels or centripetal cholesterol flux.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts